Tocilizumab in patients with severe COVID-19: a retrospective cohort studyGiovanni Guaraldi, Cristina Mussini, Marianna Meschiari et al.|The Lancet Rheumatology|2020Cited by 998
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.Gabriele Missale, Carlo Ferrari, Roberto Bertoni et al.|Journal of Clinical Investigation|1996Cited by 661
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A. Kondili, Stefano Vella, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 114
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized studySilvia Fargion, Gemino Fiorelli, Anna Ludovica Fracanzani et al.|The American Journal of Gastroenterology|2002Cited by 80
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 PneumoniaFrancesco Menichetti, Alessandro Mazzoni, Patrizia Popoli et al.|JAMA Network Open|2021Cited by 69